Unintentional methadone and buprenorphine exposures in children: Developing prevention messages. 2017

Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su

OBJECTIVE To develop key messages for methadone and buprenorphine safety education material based on an analysis of calls to the NYC Poison Control Center (NYC PCC) and designed for distribution to caregivers of young children. METHODS Retrospective review of all calls for children 5 years of age and younger involving methadone or buprenorphine from January 1, 2000, to June 15, 2014. A data abstraction form was completed for each case to capture patient demographics, exposure and caller sites, caller relation to patient, qualitative information regarding the exposure scenario, the product information, if naloxone was given, and the medical outcome of the case. RESULTS A total of 123 cases were identified. The ages of the children ranged from 4 days to 5 years; 55% were boys. All exposures occurred in a home environment. The majority of the calls were made to the NYC PCC by the doctor (74%) or nurse (2%) at a health care facility. Approximately one-fourth of the calls came from the home and were made by the parent (22%) or grandparent (2%). More than one-half of the exposures involved methadone (64%). Naloxone was administered in 28% of cases. Approximately one-fourth of the children did not experience any effect after the reported exposure, one-half (51%) experienced some effect (minor, moderate, or major), and there was 1 death (1%). More than one-half of the children were admitted to the hospital, with 40% admitted to critical care and 13% to noncritical care. Approximately 23% were treated and released from the hospital, and 20% were lost to follow-up or never arrived to the hospital. The remaining 4% were managed on site without a visit to the hospital. CONCLUSIONS Exposures to methadone and buprenorphine are dangerous with some leading to serious health effects. Safe storage and disposal instructions are needed for homes where children may be present.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D008691 Methadone A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3) Amidone,Biodone,Dolophine,Metadol,Metasedin,Methaddict,Methadone Hydrochloride,Methadose,Methex,Phenadone,Phymet,Physeptone,Pinadone,Symoron,Hydrochloride, Methadone
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D011039 Poison Control Centers Facilities which provide information concerning poisons and treatment of poisoning in emergencies. Centers, Poison Control,Center, Poison Control,Control Centers, Poison,Poison Control Center
D002047 Buprenorphine A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. 6029-M,Buprenex,Buprenorphine Hydrochloride,Buprex,Prefin,RX-6029-M,Subutex,Temgesic,Temgésic,6029 M,6029M,Hydrochloride, Buprenorphine,RX 6029 M,RX6029M
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females

Related Publications

Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su
August 2021, Clinical toxicology (Philadelphia, Pa.),
Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su
June 2018, Pediatrics,
Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su
November 2013, The Journal of pediatrics,
Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su
January 2010, The American journal on addictions,
Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su
January 2002, Neurotoxicology and teratology,
Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su
October 2006, Pediatrics,
Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su
February 2020, Annals of epidemiology,
Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su
January 2017, Clinical toxicology (Philadelphia, Pa.),
Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su
January 1997, Journal of the Southern Orthopaedic Association,
Lauren Schwartz, and Maria Mercurio-Zappala, and Mary Ann Howland, and Robert S Hoffman, and Mark K Su
April 1991, Hospital & community psychiatry,
Copied contents to your clipboard!